BioSpace News Archive

Q4 and full-year 2022 financial statements have revealed several companies slashing I-O pipelines. Here are just some of the factors at play.

Seamless Therapeutics launched Wednesday with $12.5 million in seed financing to develop its programmable recombinases for gene editing.

Real estate development firm Sterling Bay launches life sciences division starting with Lincoln Yards, a 320,000 square foot site on the Chicago River.

Job hopping– frequently changing jobs, typically within a short period of time – gained popularity with the onset of COVID-19 and is still popular now. Here’s what recruiters think about job hopping.

In spite of a tumultuous economy, many life science companies have started the year off strong. With plans to expand its team and pipeline in the coming year, Takeda is one of them.

The new financing will help the Boston-based biotech accelerate the development of its siRNA-based therapies for immuno-dermatology indications.

A bioprocess engineering company called OmniBRx Biotechnologies Private Limited has secured $5 million Series-A funding from SIDBI Ventures and others.

AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that Chief Medical Officer Dr. Robert O. Dillman will deliver an opening keynote at the World Immunotherapy Congress, a submeeting of the Festival of Biologics taking place Mar 20-22 in San Diego, California.

CymaBay Therapeutics, Inc. announced corporate updates and financial results for the year and fourth quarter ended December 31, 2022.

ProSomnus, Inc., the pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea, will report its fourth quarter and full year 2022 financial results after market close on Thursday, March 30, 2023.